Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and...

Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update - Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 - Novel abuse-deterrent platform...